Jenburkt Pharmaceuticals Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Jun'26

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Jun 2026 is -20.43% vs 3.74% in Mar 2026

Standalone Net Profit

QoQ Growth in quarter ended Jun 2026 is -45.71% vs 82.97% in Mar 2026

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Jun 2026 is -57.75% vs 92.05% in Mar 2026

Interest

QoQ Growth in quarter ended Jun 2026 is 0.00% vs 8.33% in Mar 2026

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Jun 2026 has fallen from Mar 2026

Compare Quarterly Results Of Jenburkt Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

35.51

93.05

-57.54

-61.84%

Other Operating Income

0.00

Total Operating income

35.51

93.05

-57.54

-61.84%

Raw Material Cost

2.32

43.82

-41.50

-94.71%

Purchase of Finished goods

5.48

0.51

4.97

974.51%

(Increase) / Decrease In Stocks

-1.47

-4.86

3.39

69.75%

Employee Cost

13.03

18.14

-5.11

-28.17%

Power Cost

0.00

Manufacturing Expenses

-0.01

0.00

-0.01

Selling and Distribution Expenses

0.00

Other Expenses

10.14

33.03

-22.89

-69.30%

Total Expenditure (Excl Depreciation)

29.49

90.64

-61.15

-67.46%

Operating Profit (PBDIT) excl Other Income

6.02

2.41

3.61

149.79%

Other Income

1.51

0.99

0.52

52.53%

Operating Profit (PBDIT)

7.53

3.40

4.13

121.47%

Interest

0.13

3.64

-3.51

-96.43%

Exceptional Items

0.00

Gross Profit (PBDT)

7.40

-0.24

7.64

3,183.33%

Depreciation

0.64

5.17

-4.53

-87.62%

Profit Before Tax

6.77

-5.42

12.19

224.91%

Tax

0.88

-1.55

2.43

156.77%

Provisions and contingencies

0.00

Profit After Tax

5.89

-3.88

9.77

251.80%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

5.89

-3.88

9.77

251.80%

Equity Capital

4.41

53.55

-49.14

-91.76%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

13.36

-0.72

14.08

1,955.56%

Diluted Earnings per share

13.34

-0.72

14.06

1,952.78%

Operating Profit Margin (Excl OI)

16.95%

2.59%

0.00

14.36%

Gross Profit Margin

20.84%

-0.26%

0.00

21.10%

PAT Margin

16.59%

-4.17%

0.00

20.76%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 35.51 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is -20.43% vs 3.74% in Mar 2026

YoY Growth in quarter ended Jun 2026 is -0.06% vs 9.19% in Jun 2025

Quarterly - Standalone Net Profit

Standalone Net Profit 5.89 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is -45.71% vs 82.97% in Mar 2026

YoY Growth in quarter ended Jun 2026 is -24.39% vs 4.99% in Jun 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 6.02 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is -57.75% vs 92.05% in Mar 2026

YoY Growth in quarter ended Jun 2026 is -32.81% vs -3.55% in Jun 2025

Quarterly - Interest

Interest 0.13 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 0.00% vs 8.33% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 18.18% vs 0.00% in Jun 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 16.95%

in Jun 2026

Figures in %

QoQ Growth in quarter ended Jun 2026 has fallen from Mar 2026

YoY Growth in quarter ended Jun 2026 has fallen from Jun 2025